Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048364 | 0.93 | ACKR3 (0.57) | KMT2AACKR3EPHX2EPHX1ADRA1A | |
| SCHEMBL16143727 | 0.83 | EPHX2 (0.42) | EPHX2EPHX1 | |
| SCHEMBL4046657 | 0.83 | KMT2A (0.53) | KMT2AACKR3EPHX2CCR2ADRA1D | |
| SCHEMBL2972836 | 0.82 | MEN1 (0.50) | KMT2AEPHX2EPHX1MEN1 | |
| SCHEMBL2987472 | 0.82 | NPSR1 (0.48) | KMT2AEPHX2ALDH1A1SIGMAR1MEN1 | |
| SCHEMBL2983320 | 0.81 | POLB (0.59) | KMT2AALDH1A1MEN1 | |
| SCHEMBL2985459 | 0.81 | POLB (0.59) | KMT2AALDH1A1MEN1 | |
| SCHEMBL206481 | 0.81 | MAPT (0.51) | KMT2AALDH1A1MEN1 | |
| SCHEMBL7168651 | 0.77 | EPHX2 (0.62) | KMT2AACKR3EPHX2EPHX1ALDH1A1 | |
| SCHEMBL207001 | 0.77 | FKBP1A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751088-B1 | OXO-SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | claimed |
| US-7476763-B2 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2009-01-13 | — | — | US | claimed |
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-04-19 | — | — | US | claimed |
| EP-1751088-B1 | OXO-SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-7476763-B2 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088034-A1 | Oxo-substituted cyclohexyl-1,4-diamine compounds | AOC1, ODC1, OTC | KMT2A 3911/4885ACKR3 3574/4885EPHX2 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.